Entry Detail



General Information

Database ID:exR0095775
RNA Name:hsa-miR-19a-3p
RNA Type:miRNA
Chromosome:chr13
Starnd:+
Coordinate:
Start Site(bp):91350939End Site(bp):91350961
External Links:hsa-miR-19a-3p



Disease Information

Disease Name:Borderline Ovarian Tumor
Disease Category:Cancers
MeSH ID:D010051
Type:Neoplasms/Urogenital Neoplasms
Alias:Ovarian Neoplasms//Neoplasm, Ovarian//Ovarian Neoplasm//Ovary Neoplasms//Neoplasm, Ovary//Neoplasms, Ovary//Ovary Neoplasm//Neoplasms, Ovarian//Ovary Cancer//Cancer, Ovary//Cancers, Ovary//Ovary Cancers//Ovarian Cancer//Cancer, Ovarian//Cancers, Ovarian//Ovarian Cancers//Cancer of Ovary//Cancer of the Ovary



Expression Detail

GEO ID:GSE106817
Description:Integrated extracellular microRNA profiling for ovarian cancer screening
Experimental Design:Cancer vs Control
Case Disease Type:Benign Ovarian Disease
Case Disease SubType:NA
Case Sample:Borderline Ovarian Tumor
Control Sample:Non-Cancer
Number of Case:29
Number of Control:2759
Number of Samples:2788





Regulatory Relationship

mRNA targets:
Gene SymbolChromosomeStart Site(bp)End Site(bp)Strand
ATP6V1B2
chr8
20197381
20226819
+
BCL7A
chr12
122019422
122062044
+
BRWD1
chr21
39184176
39321559
-
BTBD7
chr14
93237550
93333092
-
CAMTA1
chr1
6785454
7769706
+
CASP2
chr7
143288215
143307696
+
CCDC47
chr17
63745255
63776351
-
DNAJC16
chr1
15526813
15592379
+
HIP1
chr7
75533298
75738962
-
HOMER1
chr5
79372636
79514134
-
MEF2D
chr1
156463727
156500779
-
MYLIP
chr6
16129086
16148248
+
RCOR1
chr14
102592649
102730561
+
RFX1
chr19
13961530
14007039
-
RPS23
chr5
82273320
82278396
-
TMEM181
chr6
158536436
158635428
+
ATF7IP
chr12
14365632
14502935
+
CAMSAP1
chr9
135808487
135907546
-
CDS1
chr4
84583127
84651334
+
CHIC1
chrX
73563200
73687102
+
DTL
chr1
212035553
212107400
+
MARCKS
chr6
113857345
113863475
+
SCYL2
chr12
100267140
100341715
+
SPAG7
chr17
4959226
4967817
-
SPOPL
chr2
138501770
138573547
+
STK33
chr11
8391868
8594289
-
TNFRSF12A
chr16
3018445
3022383
+
miRNA targets:NA
circRNA targets:
circRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
hsa_circ_0001454
chr4
154524454
154533552
+
hsa_circ_0001186
chr21
35475133
35475818
+
hsa_circ_0000384
chr12
27867712
27877119
+
hsa_circ_0001605
chr6
42903447
42905047
+
hsa_circ_0000155
chr1
168007608
168014465
+
hsa_circ_0001495
chr5
68470703
68471364
+
hsa_circ_0000943
chr19
47421744
47440665
+
hsa_circ_0001164
chr20
45891031
45923523
-
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AC005394.2
chr19
28435388
28727680
-
AC010997.3
chr10
75279726
75401246
-
AC011498.2
chr19
4447304
4448217
+
AC011503.2
chr19
23927788
23929287
+
AC021078.1
chr5
149494314
149504670
-
AC135050.6
chr16
31122235
31124064
+
AL049840.4
chr14
103694516
103695050
-
AL158206.1
chr9
19453209
19455173
+
AL158825.2
chr9
75009828
75016036
-
H19
chr11
1995176
2001470
-
HAGLR
chr2
176164051
176188958
-
LAMTOR5-AS1
chr1
110347116
110443817
+
LINC00667
chr18
5237826
5290608
+
MCM3AP-AS1
chr21
46229196
46259390
+
NEAT1
chr11
65422774
65445540
+
SNHG20
chr17
77086716
77099902
+
XIST
chrX
73820649
73852723
-
Display:



Experiment Detail

GEO ID:GSE106817
Sample Source:Blood
Source Fraction:Serum
Platform:GPL21263
Method:Microarray
Num of detected RNA Type:1
Num of detected RNAs of this Type:2535
Sample treatment protocol:NA
RNA Extract protocol:Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).
RNA library preparation protocol:miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.



Reference

PMID:30333487
Title:Integrated extracellular microRNA profiling for ovarian cancer screening
Author:Yokoi A, Matsuzaki J, Yamamoto Y, Yoneoka Y, Takahashi K, Shimizu H, Uehara T, Ishikawa M, Ikeda SI, Sonoda T, Kawauchi J, Takizawa S, Aoki Y, Niida S, Sakamoto H, Kato K, Kato T, Ochiya T
Journal:Nat Commun. 2018 Oct 17;9(1):4319.
Description:to develop an optimal detection method, we use microarrays to obtain comprehensive miRNA profiles from 4046 serum samples, including 428 patients with ovarian tumors.